Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Douglas_Williams
|
| gptkbp:focusesOn |
exosome therapeutics
|
| gptkbp:foundedIn |
2015
|
| gptkbp:founder |
gptkb:Eric_Lander
gptkb:Tillman_Gerngross gptkb:Douglas_Williams gptkb:Steven_Gillis Avak Kahvejian |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Codiak BioSciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
exoIL-12
exoSTING |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
oncology
immunotherapy |
| gptkbp:status |
filed for bankruptcy in 2023
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CDAK
|
| gptkbp:website |
https://www.codiakbio.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
|
| gptkbp:bfsLayer |
7
|